IMBRUVICA ® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news